Recovery story, page-39

A stellar first-quarter result for Bubs, with a clear turnaround across all operational metrics, revenues and profits showing strong growth.

For a small-cap growth stock, It’s a clear signal the company has turned the corner and is well-positioned for further upside.

The market has recently been rewarding microcap companies that have achieved positive cash flow, such as Pointerra and Pentanet.

Here is a snapshot again of bubs reporting a standout 1H25 which includes the following;

- Positive EBITDA of $2.9m vs. $8.6m loss a year ago

- quarter operating cash inflow of $3.9m vs. $13.0m outflow a year ago

- gross revenue of $32.9m (net revenue of $28.7m, up 42%)

- FDA approval decision expected in October 2025

- reafirmed FY25 guidance including $102m revenue, gross margin of over 40% and EBITDA breakeven